低分子肝素钙对早发型重度子痫前期患者后血清sFlt-1及PAPP-A表达水平影响

doi:10.3969/j.issn.1006-6233.2023.12.031

Abstract
Figure/Table
References
Related Citation (0)

Download: PDF (1200 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the therapeutic mechanism of Nicardipine combined with low molecular weight heparin calcium by detecting the expression levels of soluble fms-like tyrosine kinase 1 (sFlt-1) and pregnancy-associated plasma protein-A (PAPP-A) in patients with early-onset severe preeclampsia. Methods: Sixty-four pregnant women with early-onset severe preeclampsia, voluntarily opting for vaginal delivery, were selected from Chengde Maternal and Child Health Hospital between April 2021 and April 2022, with gestational age ranging from 26 to 34 weeks. The patients were randomly divided into a study group and a control group, with 32 cases in each group. The control group received Nicardipine treatment, while the study group received a combination of Nicardipine and low molecular weight heparin calcium. Peripheral blood samples were collected before treatment and at 1 week of treatment. Enzyme-linked immunosorbent assay (ELISA) was used to detect serum levels of sFlt-1, placental growth factor (PLGF), and PAPP-A. Peripheral blood routine and renal function were also examined. The average gestational age at delivery was recorded. Results: Before treatment, there were no significant differences in the levels of sFlt-1, PLGF, PAPP-A, packed cell volume (PCV), creatinine (Cr), and blood urea nitrogen (BUN) between the two groups (P>0.05). Compared with pre-treatment levels, after treatment, both groups showed a decrease in sFlt-1, PCV, Cr, and BUN levels, and an increase in PLGF and PAPP-A levels, with statistically significant differences (P<0.05). When comparing the study group with the control group after treatment, the study group exhibited a significant decrease in sFlt-1, PCV, Cr, and BUN levels, and a significant increase in PLGF and PAPP-A levels (P<0.05). The average gestational age at delivery in the study group was significantly higher than that in the control group, with a statistically significant difference (P<0.05). Conclusion: Nicardipine combined with low molecular weight heparin calcium contributes to the recovery of placental function, improves renal function, delays disease progression, optimizes pregnancy indicators, prolongs gestational weeks, and effectively treats patients with early-onset severe preeclampsia.

Key words： Early-onset severe preeclampsia Low-molecular-weight heparin calcium Soluble fms-like tyrosine kinase 1 Serum placental growth factorr

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.12.031 OR http://www.hbyxzzs.cn/EN/Y2023/V29/I12/2097